Project Grant R01CA294033
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$460K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute (DFCI) to conduct research on the genetic factors underlying immune-related adverse events (IRAEs) associated with immune checkpoint inhibitor (ICI) cancer treatments. The key objectives are to: 1) Perform the largest genome-wide association study (GWAS) of IRAEs across over 13,000 ICI-treated patients, to identify shared and...
This Project Grant award of $127,629, provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, supports a multi-omic research study on the role of human leukocyte antigen (HLA) variations in immune response and efficacy of immune checkpoint inhibitor (ICI) monotherapy for non-small cell lung cancer (NSCLC). The key products and services to be delivered under this 2-year award include: Identifying the mechanisms linking germline and somatic HLA...
This federal Project Grant award of $194,022, awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports research to develop deep learning models that integrate radiology, histopathology, and clinico-genomic data to predict response to immune checkpoint inhibitor (ICI) therapy for brain metastases. The awardee, The General Hospital Corporation...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $762,258 to Cedars-Sinai Medical Center to conduct a cluster randomized controlled trial. The project aims to assess whether providing natural language processing (NLP)-based feedback with artificial intelligence (AI) summaries of key treatment tradeoffs to patients and physicians after prostate cancer consultations can improve patient decision-making and physician risk...
This Project Grant award of $657,934 from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) is focused on developing a more precise and broadly applicable neoantigen prediction algorithm for personalized cancer immunotherapy. The key products and services to be delivered include: Generation of a multi-omic dataset of immunologically validated neoantigens by collecting and utilizing biobanked tissue samples from cancer patients treated with...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...
This Project Grant award of $858,186 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) supports research by The General Hospital Corporation (doing business as Massachusetts General Hospital) to decipher the mechanisms leading to immune-related myocarditis, a fatal adverse event associated with immune checkpoint inhibitor (ICI) cancer therapies. The research aims to identify novel...
This $700,611 Project Grant, awarded on March 11, 2025 by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, supports a practical randomized controlled trial (RCT) of artificial intelligence (AI) for melanoma diagnosis at Memorial Sloan Kettering Cancer Center (MSK) and Stanford University (SU). The goal is to determine the potential benefits and barriers to clinical adoption of AI-assisted dermoscopy, and to evaluate the impact on the...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...